Valneva will present its single-dose Chikungunya vaccine

0

HolyHerblain (France), June seven, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a vaccine company, today announced that it will present its single-shot chikungunya vaccine candidate VLA1553 on June 9, 2022 at the 8th North Conference -European Conference on Travel Medicine (NECTM8) in Rotterdam.

Vera Bürger, Director Clinical Strategy at Valneva, will present a summary on the clinical development of VLA1553.

In addition, Valneva will organize a symposium on Friday, June 10, 2022 at 12:30 p.m. CEST. The symposium “Technology, Demographic and Climate Change: Increased Risk of Mosquito-borne Diseases” will feature Assistant Professor Johanna Lindahl, PhD., who will discuss the risk and protection against mosquito-borne diseases using the example of Japanese encephalitis, and Prof. Tomas Jelinek, MD, which will focus on chikungunya as a public health threat.

Valneva, a gold sponsor of NECTM8, will have a display in the exhibit area at booth #8.

For more details on the presentation, symposium and conference registration, please visit the event website: https://mkon.nu/nectm_8.

Presentation details

Event: 8th North European Conference on Travel Medicine (June 8-10, 2022)

Venue: International Conference Center De Doelen Rotterdam

Schouwburgplein 50

Rotterdam, Netherlands

Title of Presentation: Clinical Development of a Single-Dose Live Attenuated Chikungunya Vaccine Candidate

Date: Thursday, June 9, 2022

Time: 9:00 a.m. CEST

About Chikungunya
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. The infection causes symptomatic illness in 72-92% of humans four to seven days after the mosquito bite. While mortality with CHIKV is low, morbidity is high. Clinical symptoms include acute onset of fever, debilitating joint and muscle pain, headache, nausea, rash, and chronic arthralgia. The Chikungunya virus often causes large, sudden epidemics with high attack rates, affecting one third to three quarters of the population in areas where the virus is circulating. High-risk infection areas for travelers are where mosquitoes carrying the chikungunya virus are endemic, including the Americas, parts of Africa, and Southeast Asia, and the virus has spread in over 100 countries. As of September 2020, there were over three million reported cases in the Americas1 and the economic impact is considered significant. The medical and economic burden is expected to increase as the primary mosquito vectors of CHIKV continue to spread geographically. There are no preventive vaccines or effective treatments available, and as such, chikungunya is considered a major threat to public health.

About VLA1553
VLA1553 is an investigational single-dose live attenuated vaccine candidate targeting the chikungunya virus, which has spread to more than 120 countries. It was designed by removing part of the chikungunya virus genome.
Valneva published final data from pivotal Phase 3 trial of VLA1553 in March 20222 and final batch-to-batch consistency results in May 20223.
VLA1553 would expand Valneva’s existing commercial vaccine portfolio and, as such, Valneva intends to commercialize this vaccine, if approved, by leveraging its existing manufacturing and commercial operations. The global market for chikungunya vaccines is estimated to exceed $500 million per year by 20324.
To make VLA1553 more accessible to low- and middle-income countries (LMICs), Valneva and Instituto Butantan in Brazil signed an agreement in January 2021 for the development, manufacturing and commercialization of VLA15535. The collaboration is part of the agreement signed between CEPI and Valneva in July 20196which provides funding of up to $23.4 million with support from the European Union’s Horizon 2020 program.

About Valneva SE
Valneva is a vaccines company focused on the development, production and commercialization of prophylactic vaccines against infectious diseases with significant unmet medical needs. The Company takes a highly specialized and targeted approach to vaccine development, then applies its extensive knowledge of vaccine science to develop prophylactic vaccines against these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a wide range of candidate vaccines in and through the clinic, including candidates against Lyme disease, chikungunya and COVID-19.

Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
Vice President, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
[email protected]

Joshua Drumm, Ph.D.
Vice President, Global Investor Relations
M +001 917 815 4520
[email protected]

Forward-looking statements

This press release contains certain forward-looking statements relating to Valneva’s business, including with respect to the progress, timing, results and completion of the research, development, clinical trials and regulatory review of VLA1553. Furthermore, even if the actual results or developments of Valneva are consistent with the forward-looking statements contained in this press release, such results or developments of Valneva may not be indicative of future results. In some instances, you can identify forward-looking statements by words such as “could”, “should”, “may”, “expect”, “anticipate”, “believe”, “intend”, “estimates”, “aims”, “targets” or similar words. These forward-looking statements are based on Valneva’s current expectations as of the date of this press release and are subject to a number of known risks and uncertainties and unknowns and other factors that may cause actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Valneva’s expectations could be affected by, among other things, uncertainties related to the development and manufacturing of vaccines, unexpected clinical trial results, regulatory actions or delays, general competition, currency fluctuations, the impact marks heys global and European credit crisis, the ability to obtain or maintain patent or other proprietary intellectual property protection, the cancellation of existing contracts, including but not limited to the supply agreement VLA2001 with the UK government, and the impact of the COVID-19 pandemic, the occurrence of any of these elements could have a material adverse effect on the business, financial condition, prospects and results of Valneva’s operations. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this presentation will actually materialize. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


1 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas. https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-en.html. Last accessed October 13, 2020.
2 Valneva successfully completes pivotal Phase 3 trial of single-shot Chikungunya vaccine candidate
3 Valneva Successfully Completes Lot-to-Lot Consistency Trial for Its Single-Shot Chikungunya Vaccine Candidate
4 VacZine Analytics Chikungunya Virus Vaccines Global Demand Analysis. February 2020
5 Valneva and Institute Butantane Signing of a final agreement on the single-dose chikungunya vaccine for Low and middle income Countries
6 CEPI awards up to $23.4 million to Valneva for advanced development of single-dose Chikungunya vaccine

  • 2022_06_07_VLA_NECTM_PR_FR_Final


Source link

Share.

Comments are closed.